RxDoctor Payments Data

Kimberley Keel, NP

Nurse Practitioner · Calhoun, GANPI 1174943245

Payments from drug & device makers

$2,693in general payments, 2019–2025

Across 95 payments — averaging $28.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$419
  • Otsuka America Pharmaceutical, Inc.$306
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$210
  • AstraZeneca$192
  • Atricure, Inc.$187
  • Seagen Inc.$175
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,18681%
  • Education$50719%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,693 in reported general payments places this provider in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$16,948
Medicare patients
146
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$83,545
EntrestoSacubitril/Valsartan59$48,440
FarxigaDapagliflozin Propanediol29$21,001
JardianceEmpagliflozin15$10,085
Metoprolol Succinate57$702
Potassium Chloride35$686
Isosorbide Mononitrate ErIsosorbide Mononitrate46$627
Rosuvastatin Calcium58$540
Torsemide17$457
Ezetimibe20$336
Amlodipine Besylate60$290
Warfarin Sodium15$205
Metoprolol Tartrate28$199
Nitroglycerin13$184
Lisinopril27$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$83,54592 claims
NovartisEntresto$419$48,44059 claims
AstraZenecaFarxiga$192$21,00129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Calhoun

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →